PediaMine 6% Injection

Adult dosage

For infants and children over 10 kg, intravenous drip of total amino acids is increased to 20 to 25 g per day, with an increase of 1.0 to 1.25 g per kg for each kg over 10 kg. The dosage and infusion rate should be appropriately adjusted according to the patient's condition.

Children's dosage

Infants weighing 10 kg or less receive a maximum intravenous drip dose of 2.0 to 2.5 g total amino acids per kg of body weight per day.

This medication must be used strictly according to a doctor's instructions and should not be taken or stopped arbitrarily. It should not be administered to patients with hepatic encephalopathy or those at risk of hepatic encephalopathy. It is also not safe to use this medication in patients with severely impaired kidney function or those with high blood urea nitrogen levels. Patients with metabolic disorders affecting nitrogen metabolism and those with severe heart failure or pulmonary edema should also avoid this medication. This medication is not used in patients with oliguria or anuria, for whom urine output is very low or absent. It is advisable not to administer this medication to patients with elevated blood sodium or chloride levels, or those with alkalosis. Particularly when magnesium ions are included, it should not be given to patients with heart block or severe myasthenia gravis. Patients with inherited amino acid metabolic disorders or allergic reactions to the amino acids contained in this medication should also refrain from using it. If potassium ions are present above a certain concentration, it should not be administered to patients with hyperkalemia. Patients with myocardial infarction or a history of myocardial infarction are also excluded from receiving this medication. Patients with severe acidosis, congestive heart failure, edema due to sodium retention, liver disease, and kidney disease should be administered with caution. Due to the sodium bisulfite content, allergic reactions to sulfites may occur, and caution is especially needed for asthma patients. Rash and other hypersensitive reactions may rarely occur during administration, and in such cases, use should be discontinued immediately. Gastrointestinal symptoms such as nausea or vomiting may occur at times, so caution is advised. Cardiac symptoms such as chest discomfort, palpitations, rapid heartbeat, and elevated blood pressure may manifest. Rapid administration of large doses can result in acidosis, so care should be taken. Severe side effects such as chills, fever, headache, respiratory distress, respiratory arrest, shock, bronchospasm, and urinary tract spasms have been reported occasionally. Peripheral vascular dilation symptoms may occur, requiring caution. Various metabolic complications, including metabolic acidosis, hypophosphatemia, alkalosis, hyperglycemia, diabetes, osmotic diuresis, dehydration, rebound hypoglycemia, elevated liver enzymes, vitamin imbalances, electrolyte disturbances, pediatric hyperammonemia, increased BUN, serum amino acid imbalance, metabolic alkalosis, total nitrogenemia, hyperammonemia, perception loss, coma, and others, can occur. Patients with impaired liver or kidney function may have changes in blood test values, necessitating regular testing. Caution is particularly necessary regarding electrolyte balance when administering large doses or using solutions containing electrolytes. Solutions containing acetate ions may cause metabolic alkalosis, so attention is needed during use. Careful dosage should be observed to avoid fluid overload in patients with a history of renal, pulmonary, or cardiac diseases. Diabetic patients should frequently monitor their blood glucose levels during administration to ensure safety. When administering only an amino acid solution, ketone bodies may accumulate in the blood; thus, it is advisable to simultaneously administer carbohydrates. Blood glucose, electrolytes, protein, kidney and liver function, acid-base balance, and hydration status should be regularly checked to monitor treatment progress. Caution is warranted when using this medication concurrently with the specific antibiotic tetracycline, as it may reduce the efficacy of amino acids. When magnesium ions are included, interactions with calcium injections may lead to side effects, requiring caution. Its safety has not been established in pregnant women, and it should only be used when the therapeutic benefit outweighs the risk. When administering to children or infants, caution is needed to maintain a low concentration and frequently check blood ammonia levels due to potentially immature liver function. Elderly patients may have reduced bodily function; therefore, caution is necessary in adjusting the rate of administration and dosage. This medication contains electrolytes, so electrolyte balance should always be checked with high doses. Intravenous infusion should be done slowly, as rapid infusion may cause chills or vomiting. The solution should be warmed to body temperature before use, and it should be prepared in a sterile manner with clean injection equipment. Prior to administration, confirm that the solution is clear, and do not use solutions that are discolored or leaking. During storage, do not open the package, and any remaining solution should be used within 24 hours after opening. If crystals form in the solution, they should be gently melted and used after cooling to body temperature.

Serious side effects

• Urticaria
• respiratory distress
• asthma attacks
• shock
• bronchospasm
• liver failure
• kidney failure
• liver abnormalities (jaundice)
• severe edema or urinary abnormalities

Mild side effects

• Rash
• nausea
• vomiting
• chest discomfort
• palpitations
• rapid heartbeat (tachycardia)
• elevated blood pressure
• metabolic acidosis
• hypophosphatemia
• alkalosis

This medication should be stored in a sealed container, ensuring that air and moisture do not enter. It is advisable to maintain a storage temperature between 1 degree and 30 degrees Celsius at room temperature. Proper storage will safely maintain the medication's efficacy.

Appearance

A colorless to pale yellow transparent solution in a colorless transparent glass or polypropylene container as an injectable preparation.

Package unit

100mL/box